The women’s health diagnostics market is projected to reach USD 36.6 billion by 2025 from USD 25.0 billion in 2020, at a CAGR of 7.9% during the forecast period. The growing awareness about various health-related disorders, rising incidence of chronic and lifestyle disorders, and the high prevalence of infectious diseases such as HIV and hepatitis in women across the globe, increasing adoption of POC diagnostic testing and the growth in the number of diagnostic and imaging centers support the growth of the market.
Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=128928901
The market for women's health diagnostics has been growing steadily over the years, driven by several factors. These include an increasing awareness of women's health issues, advancements in diagnostic technologies, rising prevalence of gynecological cancers and other female-specific conditions, and a growing emphasis on preventive healthcare.
Key segments within the women's health diagnostics market include:
Breast Cancer Diagnostics: Breast cancer is one of the most common cancers in women. Diagnostic tests such as mammography, breast ultrasound, breast MRI, and biopsy techniques are used for early detection, diagnosis, and monitoring of breast cancer.
Cervical Cancer Diagnostics: Cervical cancer is primarily caused by human papillomavirus (HPV) infection. Diagnostic tests like Pap smear, HPV testing, colposcopy, and cervical biopsy are utilized to screen and diagnose cervical cancer.
Pregnancy and Fertility Testing: Diagnostic tests for pregnancy detection, monitoring fetal health, assessing gestational age, and evaluating fertility issues are crucial in women's healthcare. This includes urine and blood tests, ultrasound imaging, and genetic testing.
Ovarian and Gynecological Cancer Diagnostics: Diagnostic tools such as pelvic exams, transvaginal ultrasound, CA-125 blood test, and biopsies aid in detecting and diagnosing ovarian and other gynecological cancers.
Hormonal and Menopause Testing: Hormonal imbalances and menopause-related issues require diagnostic tests to assess hormone levels, such as estrogen, progesterone, and follicle-stimulating hormone (FSH) tests.
Sexually Transmitted Infections (STI) Testing: Diagnostic tests like DNA amplification tests, nucleic acid tests, and immunoassays are utilized for the detection of various sexually transmitted infections like HIV, HPV, chlamydia, gonorrhea, and syphilis.
The hospitals & clinics segment is expected to account for the largest share of the women’s health diagnostics market
Based on end user, the women’s health diagnostics market is segmented into hospitals & clinics, diagnostic & imaging centers, and home care settings. The hospitals & clinics segment accounted for the largest share of the women’s health diagnostics market. The large share of this segment can be attributed to a greater proportion of patients (women) visiting hospitals to diagnose/treat health issues.
Asia Pacific is expected to account for the highest CAGR for players operating in the women’s health diagnostics market
The Asia Pacific women’s health diagnostics market is expected to grow at the highest CAGR from 2020 to 2025. Improving healthcare infrastructures, growing per capita incomes, and the rising focus of key market companies in this region are major factors driving the growth of the APAC women’s health diagnostics market. Countries like India, China, and South Korea are expected to offer significant growth opportunities for companies operating in this market.
Key Market Players
The prominent players in this market are Quest Diagnostics Incorporated (US), Hologic, Inc. (US), Abbott Laboratories (US), Siemens AG (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), Cardinal Health, Inc. (US), General Electric Company (US), and Becton, Dickinson and Company (US).
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=128928901
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
Sign in to leave a comment.